4 ms·
Considering most drugs fail to get to market, I’d offer that the profit margins aren’t all that good if you start from scratch. Saying profit margins are too h
by refurb 8y ago
Considering most drugs fail to get to market, I’d offer that the profit margins aren’t all that good if you start from scratch.
Saying profit margins are too high is easy if you just count the winners.
- Retric 8y agoMarketing is a larger cost than Reseach for major drug companies.
- chimeracoder 8y ago> Marketing is a larger cost than Reseach for major drug companies. People on HN love to point this out, as if it somehow implies that companies are wasting money. Marketing is how companies secure their revenues from the drugs that do make it to market. Without marketing, they'd have even less money to spend on R&D. (And yes, marketing takes place in countries besides the US. Marketing is more than just consumer advertising).
- refurb 8y agoThis trope is always pulled out but it’s wrong. The analysis looked at S&GA which represented far more than marketing. Second, marketing produces a positive ROI (or why else do it). So you spend $10M on marketing and get more than $10M back. Third, you can’t sell a drug without some type of marketing. I know HN is full of engineers who build products that sell themselves, but that’s BS. Doctors often have misconceptions or lack information about new drugs and getting someone in front of them to educate them is necessary.
- paulryanrogers 8y agoGreat, let's outlaw marketing to patients. Then paid experts can deliver independently produced research directly to doctors.
- Retric 8y agoDoctors fall to marketing all the time. Even just hearing something mentioned makes it easier to jump to conclusions and rarely for the better.
- Retric 8y agoPositive ROI relating to prescribing people useless and often harmful drugs. Just look at prescriptions that just happen to fall off after drugs go generic. People are also buying insurance which is priced based on the assumption people will get useless prescriptions. So, this advertising really adds a lot more costs without nessisarily any net benefits.
- heyxub 8y agoI think counting the losers is the great rhetorical trick pulled on the public by the pharmaceutical industry. In what other industry do organizations get away with charging customers such exorbitant amounts of money to cover their failures?
- akovaski 8y ago"Counting the losers" is part of R&D. Many companies invest in R&D, having failures is normal. According to Investopia[0], pharma companies float around the top of R&D spending. They indicate the semiconductor industry gets away with charging customers with more R&D spending. (Note, Investopedia doesn't cite any sources, so take it with a grain of salt.) [0] https://www.investopedia.com/ask/answers/060115/how-much-drug-companys-spending-allocated-research-and-development-average.asp https://www.investopedia.com/ask/answers/060115/how-much-dru...
- flexer_850 8y agoGP here. Using throwaways for privacy. Don't believe the hype. The total R&D cost of an entire industry has a tenuous connection to those for a single product or organization. The lion's share of early stage R&D in pharmaceuticals happens in academia or start ups. The big players "acquire" the successful ones somewhere around phase II trials. In the semiconductor industry, like pharma, failed startups go out of business and disappear. Intel would get laughed out of the room if they tried to claim the R&D costs of such failures as their own. Yet for some reason everyone buys this argument from the pharmaceutical companies.